Trial Profile

A Clinical Trial to Assess the Effect of Ridaforolimus (AP23573; MK-8669) on QTc Interval in Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ridaforolimus (Primary)
Indications Cancer
Focus Adverse reactions
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
14 May 2010 Actual patient number (23) added as reported by ClinicalTrials.gov.
28 Apr 2010 Planned end date changed from 1 May 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com